Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?

被引：1
|
作者：
Spieler, Benjamin Oren
Lopes, Gilberto
Dal Pra, Alan
Diwanji, Tejan
Yechieli, Raphael
Freedman, Laura M.
Mihaylov, Ivaylo
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Miami, Parkland, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9579
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
    Stuart, Jessica
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Nishino, Mizuki
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Checkpoint Inhibitor Pneumonitis in Patients with Advanced NSCLC on Nivolumab Monotherapy is Underreported and Associated with Prior Radiotherapy History
    Spieler, B.
    Azzam, G.
    Kwon, D.
    Saravia, D.
    Lopes, G.
    Dal Pra, A.
    Diwanji, T., Jr.
    Yechieli, R.
    Freedman, L. M.
    Mihaylov, I. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E89 - E90
  • [3] The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients
    Jo, H.
    Yoshida, T.
    Yagishita, S.
    Shinno, Y.
    Okuma, Y.
    Goto, Y.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer
    Mao, S.
    Liu, Y.
    Zhou, F.
    Xiong, A.
    Chen, B.
    Gao, G.
    Yu, J.
    Wu, F.
    He, Y.
    Chen, X.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S383 - S383
  • [5] Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study
    Li, Xiao-Ping
    Zhang, Wei-Dong
    Li, Ming-Jiang
    Wang, Juan
    Lian, Jie
    Zhou, Hong-Gang
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [6] Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
    Pelizzari, G.
    Corvaja, C.
    Targato, G.
    Buriolla, S.
    Bortolot, M.
    Torresan, S.
    Fantin, A.
    De Maglio, G.
    Rossetto, C.
    Rizzato, S.
    Fasola, G.
    Follador, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
  • [7] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [8] Hyperprogressive Disease in Non-Small Cell Lung Cancer on pd-1 Inhibitor.
    Jang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S579 - S579
  • [9] The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
    Xiaoyang Zhai
    Jian Zhang
    Yaru Tian
    Ji Li
    Wang Jing
    Hongbo Guo
    Hui Zhu
    Cancer Biology & Medicine, 2020, 17 (03) : 599 - 611
  • [10] Clinical determinants of immunotherapy outcomes in non-small cell lung cancer patients with checkpoint inhibitor pneumonitis
    Vathiotis, I
    Tavernaraki, K.
    Trontzas, I
    Antonogiannaki, E.
    Koukaki, E.
    Syrigos, N.
    Gkiozos, I
    Kotteas, E.
    Charpidou, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
12345